Pembro-话题@MedSci

#Pembro#

98篇内容 | 2716人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1786976, encodeId=c3ae1e8697636, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=JAMA Oncol：Pembrolizumab为晚期胃或胃食管交界部腺癌三线治疗带来新希望, objectType=article, longId=132933, objectId=f4c613293337, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4c613293337, replyNumber=0, likeNumber=56, createdTime=2018-12-25, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4c613293337, moduleTitle=JAMA Oncol：Pembrolizumab为晚期胃或胃食管交界部腺癌三线治疗带来新希望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4c613293337)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786988, encodeId=b4c41e8698888, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=CLIN CANCER RES：基线肿瘤大小是接受Pembrolizumab治疗的黑色素瘤患者的独立预后因素, objectType=article, longId=152303, objectId=fde3152303bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fde3152303bb, replyNumber=0, likeNumber=69, createdTime=2019-07-02, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fde3152303bb, moduleTitle=CLIN CANCER RES：基线肿瘤大小是接受Pembrolizumab治疗的黑色素瘤患者的独立预后因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fde3152303bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786985, encodeId=d5821e86985bf, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=ANN ONCOL：Pembrolizumab治疗晚期前列腺癌, objectType=article, longId=147483, objectId=7b6414e4837a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b6414e4837a, replyNumber=0, likeNumber=60, createdTime=2018-11-20, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b6414e4837a, moduleTitle=ANN ONCOL：Pembrolizumab治疗晚期前列腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b6414e4837a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786973, encodeId=804f1e86973de, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=EUR J Cancer：使用PD-1抗体 pembrolizumab治疗转移性黑色素瘤及非黑素瘤皮肤癌中的着色性干皮症, objectType=article, longId=124993, objectId=4f6412499324, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f6412499324, replyNumber=0, likeNumber=88, createdTime=2018-12-01, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f6412499324, moduleTitle=EUR J Cancer：使用PD-1抗体 pembrolizumab治疗转移性黑色素瘤及非黑素瘤皮肤癌中的着色性干皮症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f6412499324)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786981, encodeId=d5b91e8698188, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=CLIN CANCER RES：Pembrolizumab联合聚乙二醇干扰素或Ipilimumab治疗晚期黑色素瘤或肾细胞癌, objectType=article, longId=136477, objectId=7a5f1364e7eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7a5f1364e7eb, replyNumber=0, likeNumber=58, createdTime=2018-08-19, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7a5f1364e7eb, moduleTitle=CLIN CANCER RES：Pembrolizumab联合聚乙二醇干扰素或Ipilimumab治疗晚期黑色素瘤或肾细胞癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7a5f1364e7eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786977, encodeId=636e1e86977e3, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=JAMA Oncology:Pembrolizumab为晚期胃或胃食管交界部腺癌三线治疗带来新希望, objectType=article, longId=132959, objectId=eade13295914, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=eade13295914, replyNumber=0, likeNumber=71, createdTime=2018-10-12, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=eade13295914, moduleTitle=JAMA Oncology:Pembrolizumab为晚期胃或胃食管交界部腺癌三线治疗带来新希望, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=eade13295914)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786983, encodeId=9fbc1e86983cc, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=JCO：Pembrolizumab用于难治性或复发性胸腺上皮肿瘤患者：开放性II期试验, objectType=article, longId=140934, objectId=089b1409347d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=089b1409347d, replyNumber=0, likeNumber=59, createdTime=2019-02-23, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=089b1409347d, moduleTitle=JCO：Pembrolizumab用于难治性或复发性胸腺上皮肿瘤患者：开放性II期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=089b1409347d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786982, encodeId=ed941e8698259, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=ASCO 2018：同步放化疗联合pembrolizumab巩固治疗用于不可切除III期NSCLC的II期研究, objectType=article, longId=139735, objectId=3b5d139e35b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b5d139e35b5, replyNumber=0, likeNumber=64, createdTime=2018-09-14, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b5d139e35b5, moduleTitle=ASCO 2018：同步放化疗联合pembrolizumab巩固治疗用于不可切除III期NSCLC的II期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b5d139e35b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786974, encodeId=52891e8697438, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=EUR J Cancer：Pembrolizumab治疗晚期黑色素瘤后使用伊匹单抗/nivolumab治疗的风险较低, objectType=article, longId=125181, objectId=e829125181d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e829125181d4, replyNumber=0, likeNumber=63, createdTime=2018-05-28, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e829125181d4, moduleTitle=EUR J Cancer：Pembrolizumab治疗晚期黑色素瘤后使用伊匹单抗/nivolumab治疗的风险较低, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e829125181d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786984, encodeId=f19d1e86984d4, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=CLIN CANCER RES：Pembrolizumab治疗雌激素受体阳性/HER2阴性晚期乳腺癌, objectType=article, longId=142003, objectId=8c6f142003d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c6f142003d6, replyNumber=0, likeNumber=62, createdTime=2019-05-22, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c6f142003d6, moduleTitle=CLIN CANCER RES：Pembrolizumab治疗雌激素受体阳性/HER2阴性晚期乳腺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c6f142003d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786978, encodeId=59891e869783a, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=SGO 2018 | Pembrolizumab联合Niraparib使卵巢癌患者获益, objectType=article, longId=133818, objectId=c2551338183d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2551338183d, replyNumber=0, likeNumber=68, createdTime=2019-03-08, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2551338183d, moduleTitle=SGO 2018 | Pembrolizumab联合Niraparib使卵巢癌患者获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2551338183d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786975, encodeId=034a1e8697531, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=ANN ONCOL：Pembrolizumab治疗复发性生殖细胞肿瘤, objectType=article, longId=128002, objectId=cc5312800282, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc5312800282, replyNumber=0, likeNumber=67, createdTime=2018-06-17, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc5312800282, moduleTitle=ANN ONCOL：Pembrolizumab治疗复发性生殖细胞肿瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc5312800282)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786980, encodeId=1cf51e86980ec, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=NEJM：Pembro联合化疗：非鳞状NSCLC一线治疗方案, objectType=article, longId=135819, objectId=070e135819cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=070e135819cd, replyNumber=0, likeNumber=120, createdTime=2018-08-12, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=070e135819cd, moduleTitle=NEJM：Pembro联合化疗：非鳞状NSCLC一线治疗方案, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=070e135819cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786971, encodeId=9ee51e86971bf, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=JCO：Pembrolizumab治疗晚期食管癌的安全性和抗肿瘤活性, objectType=article, longId=119453, objectId=969e1194535f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=969e1194535f, replyNumber=0, likeNumber=73, createdTime=2018-09-29, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=969e1194535f, moduleTitle=JCO：Pembrolizumab治疗晚期食管癌的安全性和抗肿瘤活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=969e1194535f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786972, encodeId=c2951e86972de, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=EUR J CANCER：转移性皮肤顶浆分泌腺癌对PD-1抗体pembrolizumab的响应, objectType=article, longId=124076, objectId=5d1f1240e680, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d1f1240e680, replyNumber=0, likeNumber=60, createdTime=2018-06-28, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d1f1240e680, moduleTitle=EUR J CANCER：转移性皮肤顶浆分泌腺癌对PD-1抗体pembrolizumab的响应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d1f1240e680)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786970, encodeId=ac5e1e86970e2, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=JCO：Pembrolizumab治疗晚期PD-L1阳性宫颈癌的安全性和有效性, objectType=article, longId=118912, objectId=d9371189127f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9371189127f, replyNumber=0, likeNumber=76, createdTime=2018-06-28, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9371189127f, moduleTitle=JCO：Pembrolizumab治疗晚期PD-L1阳性宫颈癌的安全性和有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9371189127f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786969, encodeId=c1601e86969b6, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=Lancet：Pembrolizumab与Ipilimumab用于晚期黑色素瘤的疗效对比。, objectType=article, longId=109075, objectId=1fa71090e54d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1fa71090e54d, replyNumber=0, likeNumber=85, createdTime=2018-07-25, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1fa71090e54d, moduleTitle=Lancet：Pembrolizumab与Ipilimumab用于晚期黑色素瘤的疗效对比。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1fa71090e54d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786961, encodeId=1c821e8696101, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=NEJM：Pembrolizumab作为晚期尿路上皮癌二线治疗疗效如何？, objectType=article, longId=89310, objectId=b04a893104a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b04a893104a, replyNumber=0, likeNumber=69, createdTime=2017-08-16, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b04a893104a, moduleTitle=NEJM：Pembrolizumab作为晚期尿路上皮癌二线治疗疗效如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b04a893104a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786960, encodeId=500e1e869601d, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=lancet oncol：派姆单抗（pembrolizumab）在局部晚期或转移性尿路上皮癌患者中安全性和活性的1期临床研究(KEYNOTE-012), objectType=article, longId=87698, objectId=f06c8e69880, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f06c8e69880, replyNumber=0, likeNumber=94, createdTime=2017-01-20, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f06c8e69880, moduleTitle=lancet oncol：派姆单抗（pembrolizumab）在局部晚期或转移性尿路上皮癌患者中安全性和活性的1期临床研究(KEYNOTE-012), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f06c8e69880)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1786962, encodeId=d6f41e8696283, content=<a href='/topic/show?id=38601402654' target=_blank style='color:#2F92EE;'>#Pembro#</a>, objectTitle=NEJM：Pembrolizumab二线治疗尿路上皮癌优于化疗（KEYNOTE-045）, objectType=article, longId=92485, objectId=2590924851f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2590924851f, replyNumber=0, likeNumber=76, createdTime=2017-10-20, rootId=0, userName=chendoc242, userId=8994206, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2590924851f, moduleTitle=NEJM：Pembrolizumab二线治疗尿路上皮癌优于化疗（KEYNOTE-045）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2590924851f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Pembro

2020-05-29

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

JAMA Oncol：Pembrolizumab为晚期胃或胃食管交界部腺癌三线治疗带来新希望

2018-12-25

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

CLIN CANCER RES：基线肿瘤大小是接受Pembrolizumab治疗的黑色素瘤患者的独立预后因素

2019-07-02

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

ANN ONCOL：Pembrolizumab治疗晚期前列腺癌

2018-11-20

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

EUR J Cancer：使用PD-1抗体 pembrolizumab治疗转移性黑色素瘤及非黑素瘤皮肤癌中的着色性干皮症

2018-12-01

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

CLIN CANCER RES：Pembrolizumab联合聚乙二醇干扰素或Ipilimumab治疗晚期黑色素瘤或肾细胞癌

2018-08-19

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

JAMA Oncology:Pembrolizumab为晚期胃或胃食管交界部腺癌三线治疗带来新希望

2018-10-12

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

JCO：Pembrolizumab用于难治性或复发性胸腺上皮肿瘤患者：开放性II期试验

2019-02-23

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

ASCO 2018：同步放化疗联合pembrolizumab巩固治疗用于不可切除III期NSCLC的II期研究

2018-09-14

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

EUR J Cancer：Pembrolizumab治疗晚期黑色素瘤后使用伊匹单抗/nivolumab治疗的风险较低

2018-05-28

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

CLIN CANCER RES：Pembrolizumab治疗雌激素受体阳性/HER2阴性晚期乳腺癌

2019-05-22

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

SGO 2018 | Pembrolizumab联合Niraparib使卵巢癌患者获益

2019-03-08

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

ANN ONCOL：Pembrolizumab治疗复发性生殖细胞肿瘤

2018-06-17

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

NEJM：Pembro联合化疗：非鳞状NSCLC一线治疗方案

2018-08-12

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

JCO：Pembrolizumab治疗晚期食管癌的安全性和抗肿瘤活性

2018-09-29

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

EUR J CANCER：转移性皮肤顶浆分泌腺癌对PD-1抗体pembrolizumab的响应

2018-06-28

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

JCO：Pembrolizumab治疗晚期PD-L1阳性宫颈癌的安全性和有效性

2018-06-28

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

Lancet：Pembrolizumab与Ipilimumab用于晚期黑色素瘤的疗效对比。

2018-07-25

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

NEJM：Pembrolizumab作为晚期尿路上皮癌二线治疗疗效如何？

2017-08-16

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

lancet oncol：派姆单抗（pembrolizumab）在局部晚期或转移性尿路上皮癌患者中安全性和活性的1期临床研究(KEYNOTE-012)

2017-01-20

chendoc242 (审核中...)

前往app查看评论内容

#Pembro#

NEJM：Pembrolizumab二线治疗尿路上皮癌优于化疗（KEYNOTE-045）

2017-10-20

科室
- - 订阅+
  - 更多科室
工具
服务